Active pharmaceutical ingredients supplier Novadoz Pharmaceuticals reported on Thursday the receipt of the US FDA's approval for its generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.
According to the company, Dofetilide in 125mcg, 250mcg and 500mcg capsules is AB rated to Pfizer's brand Tykosin. Oseltamivir Phosphate in 30mg, 40mg and 75mg capsules is AB rated to Genentech Pharmaceuticals' Tamiflu.
Dofetilide is an antiarrhythmic drug used sustain a normal heart beat in patients with certain heart rhythm disorders of the atrium. It is used to treat atrial fibrillation, or atrial flutter. Combined brand and generic sales for the product exceed USD63.4m.
Oseltamivir Phosphate is used to treat symptoms caused by the flu virus (influenza) including blocked nasal passages, fever/chills, aches and fatigue. Combined sales for brand and generics amount to over USD188m.
Viatris names new chief legal officer
Alvotech signs biosimilar supply and commercialisation deals with Sandoz
InSysBio agrees new collaborative project with BeOne Medicines
MS Pharma enters strategic partnership with Hetero Group
Apiject to open new generic injectable drug manufacturing facility in Apex, NC
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz